Puma Biotechnology, Inc. Share Price & Technical Analysis
PBYI · $7.08 (+0.43%)
Healthcare / Biotechnology
$7.08
+0.43%
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-5% return in May, 0% avg return in past 3 year May month.
24% return in 2026, 38% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 8% | -11% | 16% | 15% | -5% | – | – | – | – | – | – | – | 24% |
| 25 | -6% | 29% | -14% | 7% | 3% | 3% | -11% | 61% | 4% | -4% | 0% | 20% | 91% |
| 24 | 9% | 32% | 0% | -6% | -25% | -15% | 13% | -31% | 0% | 12% | 17% | -12% | -6% |
| 23 | 2% | -9% | -18% | -13% | 22% | 6% | 3% | 0% | -30% | -4% | 56% | 13% | 28% |
| 22 | -17% | -8% | 26% | -17% | -17% | 40% | 0% | -7% | -11% | -8% | 105% | -9% | 76% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Uptrend · Neutral
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$350.19M
P/E ratio
14.33
52W high
$7.90
52W low
$3.03
Volume
1,87,002
Beta
1.23
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Puma Biotechnology, Inc. share price today?
- Puma Biotechnology, Inc. (PBYI) last traded around $7.08 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PBYI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PBYI. Download the app for real-time alerts.
- How can I analyze Puma Biotechnology, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.